Eli Lilly CEO on Price Transparency, Loxo Acquisition

The transcript discusses Lilly's efforts to increase drug pricing transparency, starting with Trulicity. It highlights Lilly's acquisition of Laakso, a leader in precision medicine, to enhance its oncology business. The conversation also covers Lilly's business development strategy, focusing on smaller acquisitions and innovation in the diabetes market. The impact of generics on pricing and the importance of innovation in the pharmaceutical industry are discussed. Finally, Lilly's financial guidance and future plans, including sales growth and operating margins, are outlined.

How does Lilly plan to address pricing pressures in the diabetes market?

What is the impact of generics on the pharmaceutical industry according to the discussion?

What are the updated guidance expectations for Lilly in 2019 and 2020?